The overall purpose of our research was to improve the tumor targeting properties of radiolabeled biologicals by optimizing chemical parameters. This year we developed a semi-automated 3-column system to purify a positron emitter,Y-86 because it is a better surrogate radionuclide than In-111 currently in use to estimate dosimetry of Y-90-labeled therapeutic radiopharmaceuticals. This purification system involved the passage of Cyclotron produced Y-86 samples through a Sr-selective Sr-Spec column, a Y-selective RE-Spec column and finally a cation-exchange Aminex A5 column connected in series. This method enabled us to decontaiminate Sr by 250,000 times with >80% recovery of Y-86. We also investigated a new Tc-99m chemistry involving [Tc-99m (OH)3(CO)3]+ with Tc-99m (I) oxidation state to label biological molecules under mild conditions. The three water molecules of this complex are labile and can be substituted by a molecule with two or three coordination sites to form a stable ellipsoidal Tc-99m complex. We optimized the chemical condition to label norbiotinamido-DTPA and -EDTA with Tc-99m at 45 degree C. The animal study indicates that this approach is promising to synthesize a polar Tc-99m labeled biotin that rapidly accumulates in tumors with pretargeted antibody-streptavidin while being excreted via the renal system.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL025001-02
Application #
6825899
Study Section
(NMRR)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2003
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cho, Hong-Jun; Lee, Sung-Jin; Park, Sung-Jun et al. (2016) Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging. J Control Release 237:177-184
Shin, In Soo; Jang, Beom-Su; Danthi, S Narasimhan et al. (2007) Use of antibody as carrier of oligomers of peptidomimetic alphavbeta3 antagonist to target tumor-induced neovasculature. Bioconjug Chem 18:821-8
Jang, Beom-Su; Lim, Esther; Hee Park, Seung et al. (2007) Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice. Nucl Med Biol 34:363-70
Zhang, YuJian; Xiang, Laiman; Hassan, Raffit et al. (2006) Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 12:4695-701
Zhang, Meili; Yao, Zhengsheng; Zhang, Zhuo et al. (2006) The anti-CD25 monoclonal antibody 7G7/B6, armed with the alpha-emitter 211At, provides effective radioimmunotherapy for a murine model of leukemia. Cancer Res 66:8227-32
Sato, Noriko; Hassan, Raffit; Axworthy, Donald B et al. (2005) Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 46:1201-9
Park, Luke S; Szajek, Lawrence P; Wong, Karen J et al. (2004) Semi-automated 86Y purification using a three-column system. Nucl Med Biol 31:297-301
Yao, Zhengsheng; Zhang, Meili; Garmestani, Kayhan et al. (2004) Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N"",N""'-tetraacetic acid-biotin. Clin Cancer Res 10:3137-46
Jeong, Jae Min; Lee, Jaetae; Paik, Chang Hum et al. (2004) Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. Arch Pharm Res 27:961-7
Sato, Noriko; Park, Chang W; Kim, Hyung-Sik et al. (2003) Synthesis of dendrimer-based biotin radiopharmaceuticals to enhance whole-body clearance. Nucl Med Biol 30:617-25

Showing the most recent 10 out of 12 publications